Suppr超能文献

乌拉立肽:从肾利钠肽到临床试验

Ularitide: from renal natriuretic peptide to clinical trials.

作者信息

Meyer M, Uberbacher H J, Böhm E, Schöpe K B, Brett W, Forssmann W G

机构信息

Niedersächsisches Institute for Peptide Research, Hanover, Germany.

出版信息

Curr Opin Nephrol Hypertens. 1996 Jul;5(4):364-8. doi: 10.1097/00041552-199607000-00013.

Abstract

Ularitide is a member of the natriuretic peptide family which is presumably synthesized in the kidney. In physiological experiments a correlation between Ularitide excretion and natriuresis has been found. Ularitide infusions and bolus injections in animals initiated profound diuresis and natriuresis as the most prominent effects. On the basis of findings in in-vitro and in-vivo experiments, Ularitide was used in clinical trials, and the results indicate that it could be a promising new drug to prevent and treat acute renal failure in patients after cardiac surgery and organ transplantation.

摘要

乌拉立肽是利钠肽家族的一员,可能在肾脏中合成。在生理学实验中,已发现乌拉立肽排泄与利钠作用之间存在相关性。在动物身上输注和推注乌拉立肽引发了显著的利尿和利钠作用,这是最突出的效应。基于体外和体内实验的结果,乌拉立肽被用于临床试验,结果表明它可能是预防和治疗心脏手术及器官移植后患者急性肾衰竭的一种有前景的新药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验